Wegovy capsules and the oral semaglutide tablet — what UK patients need to know

You've spotted 'Wegovy capsules' online, here's what's actually being sold

If you searched for semaglutide capsules after seeing the phrase somewhere on social media or a supplement site, it's worth pausing. Capsules claiming to contain semaglutide are not approved medicines in the UK. They are not the same product as the Wegovy tablet approved by the MHRA, and the MHRA has consistently warned that weight-loss medicines sold without a valid UK prescription, often at suspiciously low prices, can be counterfeit or unlicensed. The safe route is straightforward: the real oral semaglutide for weight loss is a prescription-only tablet, dispensed from a GPhC-registered pharmacy after a clinician reviews your case.

The Wegovy tablet is co-formulated with an absorption enhancer called SNAC. Without it, the stomach would break semaglutide down before it reached the bloodstream. This is why the tablet must be taken first thing in the morning on an empty stomach, with a small amount of plain water, and why you need to wait at least 30 minutes before eating, drinking coffee, or taking any other oral medicine. Supplements marketed as 'semaglutide capsules' almost certainly skip this pharmacology entirely. The active molecule in a supplement capsule won't survive digestion the same way.

If you're thinking about semaglutide for weight loss in any form, the first step is a clinical consultation, not a checkout page.

What the trial evidence says about the semaglutide tablet's results

The phase 3 clinical programme for the oral Wegovy tablet (known as OASIS 4) enrolled 307 adults with obesity or overweight with at least one weight-related condition, without type 2 diabetes, over 64 weeks. Participants taking the tablet alongside lifestyle changes lost an average of around 13.6% of body weight compared with roughly 2.4% on placebo. Among those who stayed fully adherent to treatment, the average weight loss was closer to 17%, though that figure needs context: it reflects the group with the highest consistency, not a typical outcome you can plan around.

For comparison, the injectable Wegovy at 2.4 mg produced around 15% average weight loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine, and you can read more about what reaching the step 9 semaglutide dose involves for patients working through the titration schedule. The most common side effects in the OASIS 4 trial were gastrointestinal: nausea, diarrhoea, constipation, and vomiting were reported in nearly three-quarters of participants taking the active tablet, though most were mild to moderate and tended to ease as the body adjusted. You can read more about how Wegovy works across both injection and tablet forms.

Titration is gradual by design. The schedule runs 1.5 mg, then 4 mg, then 9 mg, up to the 25 mg maintenance dose, spending at least a month at each step. That pacing exists to reduce side-effect burden, not as an obstacle.

Who the tablet is licensed for, and the NHS picture right now

The MHRA has licensed the Wegovy tablet for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or prediabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. These are the licence criteria; individual suitability is always a prescriber's decision, not a tick-box exercise.

As of summer 2026, NICE has not appraised the oral tablet, so it is not commissioned on the NHS. Private prescription is the only current route. If you want to understand how demand has shifted since the injection launched, our page covering Wegovy sales trends gives useful context on how uptake has grown. The cost of Wegovy in private practice varies by provider and dose, and it's worth understanding what any quoted price includes (or doesn't) before committing. One thing worth knowing is that treatment involving no clinical review is a red flag, not a bargain.

The tablet carries a practical advantage for anyone who finds weekly injections difficult: no needles, no refrigerator, no sharps disposal. That said, the daily morning ritual before the kettle even goes on (empty stomach, small amount of water, 30-minute wait) suits some people less than a once-weekly injection. Both are valid options, and which fits your life is part of what a prescriber talks through with you. You can explore the full range of treatment options to get a clearer sense of the landscape.

What 'semaglutide capsules for weight loss' usually means in search results

The phrase 'semaglutide capsules for weight loss' circulates widely online, sometimes referring loosely to the Wegovy tablet, sometimes to unlicensed products, and occasionally to Rybelsus, the oral semaglutide tablet licensed for type 2 diabetes management, not weight loss. Rybelsus comes in 3 mg, 7 mg, and 14 mg strengths, none of which are part of the Wegovy weight-loss tablet schedule. Confusing the two products is easy but consequential; a prescriber who checks your Summary Care Record will catch a mismatch that a website won't.

The MHRA's record on semaglutide approvals is the authoritative source for what's actually licensed in the UK. If a product isn't on it, it isn't Wegovy. Our clinical team, led by our GPhC-registered prescribers, can walk through the differences and help you work out which licensed option, if any, makes clinical sense for you.

If you have questions before starting, our FAQs page covers the most common ones. When you're ready to talk it through properly, speak to our prescribers for a free, same-day consultation.